S. Weingart, E. Brown, P. Bach, K. Eng, S. Johnson et al., NCCN Task Force Report: Oral chemotherapy, J Natl Compr Cancer Netw JNCCN. mars, vol.6, pp.1-14, 2008.

T. Halfdanarson and A. Jatoi, Oral Cancer Chemotherapy: The Critical Interplay Between Patient Education and Patient Safety, Current Oncology Reports, vol.334, issue.4, pp.247-252, 2010.
DOI : 10.1007/s11912-010-0103-6

V. Régnier-denois, V. Rousset-guarato, A. Nourissat, A. Bourmaud, and F. Chauvin, Contribution of a preliminary socio-anthropological survey to the development of a therapeutic patient education programme for patients receiving oral chemotherapy. Educ Thérapeutique Patient -Ther Patient Educ, pp.101-107, 2010.

A. Jeanneret, L. Lüthi, F. Schneider, M. P. Troxler, S. Bugnon et al., Adhésion thérapeutique aux traitements oncologiques oraux et prise en charge interdisciplinaire, Rev Med Suisse, vol.75, pp.1154-1160, 2011.

A. Moreau and P. Queneau, La décision thérapeutique personnalisée. Observance médicamenteuse, La revue du praticien, vol.55, 2005.

J. Cramer, A. Roy, A. Burrell, C. Fairchild, M. Fuldeore et al., Medication Compliance and Persistence: Terminology and Definitions, Value in Health, vol.11, issue.1, pp.44-51, 2008.
DOI : 10.1111/j.1524-4733.2007.00213.x

M. Baudrant-boga, A. Lehmann, and B. Allenet, Penser autrement l???observance m??dicamenteuse??: d???une posture injonctive ?? une alliance th??rapeutique entre le patient et le soignant ??? Concepts et d??terminants, Annales Pharmaceutiques Fran??aises, vol.70, issue.1, pp.15-25, 2012.
DOI : 10.1016/j.pharma.2011.10.003

A. Lamouroux, A. Magnan, and D. Vervloet, Compliance, observance ou adhésion thérapeutique : de quoi parlons-nous ? Revue des maladies respiratoires, pp.31-34, 2005.

B. Allenet, M. Baudrant, A. Lehmann, A. Gauchet, M. Roustit et al., Comment ??valuer l???adh??sion m??dicamenteuse??? Le point sur les m??thodes, Annales Pharmaceutiques Fran??aises, vol.71, issue.2, pp.135-141, 2013.
DOI : 10.1016/j.pharma.2012.10.001

L. Fallowfield, L. Atkins, S. Catt, A. Cox, C. Coxon et al., Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer, Annals of Oncology, vol.17, issue.2, pp.205-210, 2006.
DOI : 10.1093/annonc/mdj044

E. Sabatâe and W. Organization, Adherence to Long-term Therapies: Evidence for Action, World Health, 2003.

D. Hughes, W. Cowell, T. Koncz, and J. Cramer, Methods for Integrating Medication Compliance and Persistence in Pharmacoeconomic Evaluations, Value in Health, vol.10, issue.6, pp.498-509, 2007.
DOI : 10.1111/j.1524-4733.2007.00205.x

R. Epstein, Making communication research matter: What do patients notice, what do patients want, and what do patients need?, Patient Education and Counseling, vol.60, issue.3, pp.272-278, 2006.
DOI : 10.1016/j.pec.2005.11.003

E. Frattini, P. Lindsay, E. Kerr, and Y. Park, Learning needs of congestive heart failure patients, Prog Cardiovasc Nurs, vol.13, issue.2, pp.11-16, 1998.

G. Burlingame, N. Ridge, J. Matsuno, A. Hwang, and D. Earnshaw, Educational needs of inpatients with severe & persistent mental illness: a partial replication, J Psychosoc Nurs Ment Health Serv. mai, vol.44, issue.5, pp.38-43, 2006.

V. Lamy, C. Rey, E. Franchon, M. Laramas, D. Charlety et al., Quelles attentes des patients souffrant de cancers en hôpital de jour en termes d'information sur leur traitement ? Le Pharmacien Hospitalier et Clinicien, pp.183-190, 2010.

A. Blanchet and A. Gotman, L'entretien -L'enquête et ses méthodes, Collection, vol.128, issue.19, 2005.

D. Ketele and J. , Méthodologie du recueil d'informations fondements des méthodes d'observation, de questionnaire, d'interview et d'étude de documents, 2009.

N. Berthier and C. , Les Techniques d'enquête : Méthode et exercices corrigés, 1998.

J. Ogden, Health Psychology. McGraw-Hill International, 2012.

K. Charmaz, Constructing Grounded Theory: A Practical Guide Through Qualitative Analysis, 2006.

D. Boyle and B. Bubalo, Enhancing Patient Adherence to Improve Outcomes With Oral Chemotherapy, US Pharm, vol.32, issue.10, pp.1-8, 2007.

D. Bhattacharya, C. Easthall, K. Willoughby, M. Small, and S. Watson, Capecitabine non-adherence: Exploration of magnitude, nature and contributing factors, Journal of Oncology Pharmacy Practice, vol.8, issue.1, pp.333-342, 2012.
DOI : 10.1080/08870449908407311

A. Partridge, L. Archer, A. Kornblith, J. Gralow, D. Grenier et al., Adherence and Persistence With Oral Adjuvant Chemotherapy in Older Women With Early-Stage Breast Cancer in CALGB 49907: Adherence Companion Study 60104, Journal of Clinical Oncology, vol.28, issue.14
DOI : 10.1200/JCO.2009.26.4671

A. Lebovits, J. Strain, S. Schleifer, J. Tanaka, S. Bhardwaj et al., Patient noncompliance with self-administered chemotherapy, Cancer, vol.37, issue.1, pp.17-22, 1990.
DOI : 10.1002/1097-0142(19900101)65:1<17::AID-CNCR2820650106>3.0.CO;2-I

F. Mazzeo, L. Duck, E. Joosens, L. Dirix, C. Focan et al., Nonadherence to imatinib treatment in patients with gastrointestinal stromal tumors: the ADAGIO study, Anticancer Res. avr, vol.31, issue.4, pp.1407-1409, 2011.

J. Tsang, I. Rudychev, and S. L. Pescatore, Prescription compliance and persistency in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients (pts) on imatinib (IM), ASCO Annual Meeting Proceedings (Post- Meeting Edition, pp.2418-6119, 2006.

L. Wood, A review on adherence management in patients on oral cancer therapies, European Journal of Oncology Nursing, vol.16, issue.4, pp.432-438, 2012.
DOI : 10.1016/j.ejon.2011.10.002

V. Gebbia, G. Bellavia, F. Ferraù, and M. Valerio, Adherence, compliance and persistence to oral antineoplastic therapy: a review focused on chemotherapeutic and biologic agents, Expert Opinion on Drug Safety, vol.10, issue.4, pp.49-59, 2012.
DOI : 10.1200/JOP.2010.000076

R. Chevrier, I. Praagh, P. Chollet, A. Laurent, N. Gaume et al., Évaluation de l'observance des thérapeutiques orales en oncologie : résultats d'une étude pilote, J Pharm Clin. 1 juin, vol.30, issue.2, pp.83-93, 2011.

C. Bosley, What affects patient adherence to oral chemotherapy? ONS Connect, avr, vol.27, issue.4, p.24, 2012.

K. Ruddy, E. Mayer, and A. Partridge, Patient adherence and persistence with oral anticancer treatment, CA: A Cancer Journal for Clinicians, vol.59, issue.1, pp.56-66, 2009.
DOI : 10.3322/caac.20004

S. Moore, Nonadherence in Patients With Breast Cancer Receiving Oral Therapies, Clinical Journal of Oncology Nursing, vol.14, issue.1, pp.41-47, 2010.
DOI : 10.1188/10.CJON.41-47

F. Ranchon, C. Bouret, B. Charpiat, and G. Leboucher, S??curisation de l???emploi des chimioth??rapies anticanc??reuses administrables par voie orale, Le Pharmacien Hospitalier, vol.44, issue.1, pp.36-44, 2009.
DOI : 10.1016/j.phhp.2008.12.002

G. Liu, E. Franssen, M. Fitch, and E. Warner, Patient preferences for oral versus intravenous palliative chemotherapy., Journal of Clinical Oncology, vol.15, issue.1, pp.110-115, 1997.
DOI : 10.1200/JCO.1997.15.1.110

M. Borner, P. Schoffski, R. De-wit, F. Caponigro, G. Comella et al., Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin, European Journal of Cancer, vol.38, issue.3, pp.349-358, 1990.
DOI : 10.1016/S0959-8049(01)00371-9

G. Banna, E. Collovà, V. Gebbia, H. Lipari, P. Giuffrida et al., Anticancer oral therapy: Emerging related issues, Cancer Treatment Reviews, vol.36, issue.8, pp.595-605, 2010.
DOI : 10.1016/j.ctrv.2010.04.005

C. Twelves, S. Gollins, R. Grieve, and L. Samuel, A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer, Annals of Oncology, vol.17, issue.2, pp.239-245, 2006.
DOI : 10.1093/annonc/mdj023

O. Bouché, E. Scaglia, and S. Lagarde, Prerequisites to the administration and prevention of adverse effects of chemotherapy in colorectal cancer]. Bull Cancer (Paris), févr, vol.97, issue.2, pp.265-280, 2010.

R. Halpern, V. Barghout, V. Zarosky, and D. E. Williams, Costs and utilization associated with imatinib adherence in patients with chronic myeloid leukemia or gastrointestinal stromal turmor, JCOM, vol.16, issue.5, p.215, 2009.

H. J. Henk, S. K. Thomas, W. Feng, B. Jean-francois, G. A. Goldberg et al., The impact of non-compliance with imatinib (IM) therapy on health care costs, ASCO Annual Meeting Proceedings (Post-Meeting Edition, pp.2418-6083, 2006.

L. Simon, D. Prebay, A. Beretz, J. Bagot, A. Lobstein et al., Médecines complémentaires et alternatives suivies par les patients cancéreux en France, Bull Cancer, vol.94, issue.5, pp.483-488, 2007.

S. Payne, A study of quality of life in cancer patients receiving palliative chemotherapy, Social Science & Medicine, vol.35, issue.12, pp.1505-1509, 1992.
DOI : 10.1016/0277-9536(92)90053-S

M. Amram, A. Roth, and A. Benamran, Thérapies ciblées en oncologie digestive, Revue Med Suisse. 25 mai, vol.296, issue.20, pp.1131-1136, 2011.

G. Bergers and L. Benjamin, Angiogenesis: Tumorigenesis and the angiogenic switch, Nature Reviews Cancer, vol.3, issue.6, pp.401-410, 2003.
DOI : 10.1038/nrc1093

E. Rowinsky, The erbB Family: Targets for Therapeutic Development Against Cancer and Therapeutic Strategies Using Monoclonal Antibodies and Tyrosine Kinase Inhibitors, Annual Review of Medicine, vol.55, issue.1, pp.433-457, 2004.
DOI : 10.1146/annurev.med.55.091902.104433

R. Roskoski, . Jr, . F. The-erbb1?11, R. Motzer, T. Hutson et al., HER receptor protein-tyrosine kinases and cancer Sunitinib versus interferon alfa in metastatic renal-cell carcinoma, Biochem Biophys Res Commun. 18 juin N Engl J Med. 11 janv, vol.319356, issue.12, pp.115-124, 2004.

B. Escudier, T. Eisen, W. Stadler, C. Szczylik, S. Oudard et al., Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma, New England Journal of Medicine, vol.356, issue.2, pp.125-134, 2007.
DOI : 10.1056/NEJMoa060655

C. Geyer, J. Forster, D. Lindquist, S. Chan, C. Romieu et al., Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer Capecitabine nonadherence: exploration of magnitude, nature and contributing factors, N Engl J Med. J Oncol Pharm Pr Off Publ Int Soc Oncol Pharm Pr. sept, vol.35518, issue.204, pp.5319-5339, 2006.

N. Aaronson, S. Ahmedzai, B. Bergman, M. Bullinger, A. Cull et al., The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology, JNCI Journal of the National Cancer Institute, vol.85, issue.5, pp.365-376, 1993.
DOI : 10.1093/jnci/85.5.365

W. Miller and J. Tonigan, Assessing drinkers' motivation for change: The Stages of Change Readiness and Treatment Eagerness Scale (SOCRATES)., Psychology of Addictive Behaviors, vol.10, issue.2, pp.81-89, 1996.
DOI : 10.1037/0893-164X.10.2.81

S. Weingart, E. Brown, P. Bach, K. Eng, S. Johnson et al., NCCN Task Force Report: Oral chemotherapy, J Natl Compr Cancer Netw JNCCN. mars, vol.6, pp.1-14, 2008.

T. Halfdanarson and A. Jatoi, Oral Cancer Chemotherapy: The Critical Interplay Between Patient Education and Patient Safety, Current Oncology Reports, vol.334, issue.4, pp.247-252, 2010.
DOI : 10.1007/s11912-010-0103-6

V. Régnier-denois, V. Rousset-guarato, A. Nourissat, A. Bourmaud, and F. Chauvin, Contribution of a preliminary socio-anthropological survey to the development of a therapeutic patient education programme for patients receiving oral chemotherapy. Educ Thérapeutique Patient -Ther Patient Educ, pp.101-107, 2010.

A. Jeanneret, L. Lüthi, F. Schneider, M. P. Troxler, S. Bugnon et al., Adhésion thérapeutique aux traitements oncologiques oraux et prise en charge interdisciplinaire, Rev Med Suisse La revue du praticien, vol.7, issue.55, pp.1154-1160, 2005.

A. Moreau and P. Queneau, La décision thérapeutique personnalisée. Observance médicamenteuse, La revue du praticien, vol.55, 2005.

J. Cramer, A. Roy, A. Burrell, C. Fairchild, M. Fuldeore et al., Medication Compliance and Persistence: Terminology and Definitions, Value in Health, vol.11, issue.1, pp.44-51, 2008.
DOI : 10.1111/j.1524-4733.2007.00213.x

URL : http://doi.org/10.1111/j.1524-4733.2007.00213.x

M. Baudrant-boga, A. Lehmann, and B. Allenet, Penser autrement l???observance m??dicamenteuse??: d???une posture injonctive ?? une alliance th??rapeutique entre le patient et le soignant ??? Concepts et d??terminants, Annales Pharmaceutiques Fran??aises, vol.70, issue.1, pp.15-25, 2012.
DOI : 10.1016/j.pharma.2011.10.003

A. Lamouroux, A. Magnan, and D. Vervloet, Compliance, observance ou adhésion thérapeutique : de quoi parlons-nous ? Revue des maladies respiratoires, pp.31-34, 2005.
DOI : 10.1016/s0761-8425(05)85433-6

B. Allenet, M. Baudrant, A. Lehmann, A. Gauchet, M. Roustit et al., Comment ??valuer l???adh??sion m??dicamenteuse??? Le point sur les m??thodes, Annales Pharmaceutiques Fran??aises, vol.71, issue.2, pp.135-141, 2013.
DOI : 10.1016/j.pharma.2012.10.001

L. Fallowfield, L. Atkins, S. Catt, A. Cox, C. Coxon et al., Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer, Annals of Oncology, vol.17, issue.2, pp.205-210, 2006.
DOI : 10.1093/annonc/mdj044

E. Sabatâe and W. Organization, Adherence to Long-term Therapies: Evidence for Action, World Health, 2003.

D. Hughes, W. Cowell, T. Koncz, and J. Cramer, Methods for Integrating Medication Compliance and Persistence in Pharmacoeconomic Evaluations, Value in Health, vol.10, issue.6, pp.498-509, 2007.
DOI : 10.1111/j.1524-4733.2007.00205.x

R. Epstein, Making communication research matter: What do patients notice, what do patients want, and what do patients need?, Patient Education and Counseling, vol.60, issue.3, pp.272-278, 2006.
DOI : 10.1016/j.pec.2005.11.003

E. Frattini, P. Lindsay, E. Kerr, and Y. Park, Learning needs of congestive heart failure patients, Prog Cardiovasc Nurs, vol.13, issue.2, pp.11-16, 1998.

G. Burlingame, N. Ridge, J. Matsuno, A. Hwang, and D. Earnshaw, Educational needs of inpatients with severe & persistent mental illness: a partial replication, J Psychosoc Nurs Ment Health Serv. mai, vol.44, issue.5, pp.38-43, 2006.

. Direction-de-la-recherche, des études, de l'évaluation et des statistiques La vie deux ans après le diagnostic de cancer, Collection Etudes et statistiques, 2008.

B. Van-der-molen, Relating information needs to the cancer experience: 1. Information as a key coping strategy, European Journal of Cancer Care, vol.53, issue.4, pp.238-244, 1999.
DOI : 10.1046/j.1365-2648.1993.18071125.x

V. Lamy, C. Rey, E. Franchon, M. Laramas, D. Charlety et al., Quelles attentes des patients souffrant de cancers en hôpital de jour en termes d'information sur leur traitement ? Le Pharmacien Hospitalier et Clinicien, pp.183-190, 2010.

A. Blanchet and A. Gotman, L'entretien -L'enquête et ses méthodes, Collection, vol.128, issue.19, 2005.

D. Ketele and J. , Méthodologie du recueil d'informations fondements des méthodes d'observation, de questionnaire, d'interview et d'étude de documents, 2009.

N. Berthier and C. , Les Techniques d'enquête : Méthode et exercices corrigés, 1998.

J. Ogden, Health Psychology. McGraw-Hill International, 2012.

K. Charmaz, Constructing Grounded Theory: A Practical Guide Through Qualitative Analysis, 2006.

D. Boyle and B. Bubalo, Enhancing Patient Adherence to Improve Outcomes With Oral Chemotherapy, US Pharm, vol.32, issue.10, pp.1-8, 2007.

D. Bhattacharya, C. Easthall, K. Willoughby, M. Small, and S. Watson, Capecitabine nonadherence: exploration of magnitude, nature and contributing factors, J Oncol Pharm Pr Off Publ Int Soc Oncol Pharm Pr. sept, vol.18, issue.3, pp.333-342, 2012.

A. Partridge, L. Archer, A. Kornblith, J. Gralow, D. Grenier et al., Adherence and Persistence With Oral Adjuvant Chemotherapy in Older Women With Early-Stage Breast Cancer in CALGB 49907: Adherence Companion Study 60104, Journal of Clinical Oncology, vol.28, issue.14, pp.2418-2422, 2010.
DOI : 10.1200/JCO.2009.26.4671

A. Lebovits, J. Strain, S. Schleifer, J. Tanaka, S. Bhardwaj et al., Patient noncompliance with self-administered chemotherapy, Cancer, vol.37, issue.1, pp.17-22, 1990.
DOI : 10.1002/1097-0142(19900101)65:1<17::AID-CNCR2820650106>3.0.CO;2-I

F. Mazzeo, L. Duck, E. Joosens, L. Dirix, C. Focan et al., Nonadherence to imatinib treatment in patients with gastrointestinal stromal tumors: the ADAGIO study, Anticancer Res. avr, vol.31, issue.4, pp.1407-1409, 2011.

J. Tsang, I. Rudychev, and S. L. Pescatore, Prescription compliance and persistency in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients (pts) on imatinib (IM), ASCO Annual Meeting Proceedings (Post-Meeting Edition, pp.2418-6119, 2006.

L. Wood, A review on adherence management in patients on oral cancer therapies, European Journal of Oncology Nursing, vol.16, issue.4
DOI : 10.1016/j.ejon.2011.10.002

V. Gebbia, G. Bellavia, F. Ferraù, and M. Valerio, Adherence, compliance and persistence to oral antineoplastic therapy: a review focused on chemotherapeutic and biologic agents, Expert Opinion on Drug Safety, vol.10, issue.4, pp.49-59, 2012.
DOI : 10.1200/JOP.2010.000076

R. Chevrier, I. Praagh, P. Chollet, A. Laurent, N. Gaume et al., Évaluation de l'observance des thérapeutiques orales en oncologie : résultats d'une étude pilote, J Pharm Clin. 1 juin, vol.30, issue.2, pp.83-93, 2011.

C. Bosley, What affects patient adherence to oral chemotherapy? ONS Connect, avr, vol.27, issue.4, p.24, 2012.

K. Ruddy, E. Mayer, and A. Partridge, Patient adherence and persistence with oral anticancer treatment, CA: A Cancer Journal for Clinicians, vol.59, issue.1, pp.56-66, 2009.
DOI : 10.3322/caac.20004

S. Moore, Nonadherence in Patients With Breast Cancer Receiving Oral Therapies, Clinical Journal of Oncology Nursing, vol.14, issue.1, pp.41-47, 2010.
DOI : 10.1188/10.CJON.41-47

F. Ranchon, C. Bouret, B. Charpiat, and G. Leboucher, S??curisation de l???emploi des chimioth??rapies anticanc??reuses administrables par voie orale, Le Pharmacien Hospitalier, vol.44, issue.1, pp.36-44, 2009.
DOI : 10.1016/j.phhp.2008.12.002

G. Liu, E. Franssen, M. Fitch, and E. Warner, Patient preferences for oral versus intravenous palliative chemotherapy., Journal of Clinical Oncology, vol.15, issue.1, pp.110-115, 1997.
DOI : 10.1200/JCO.1997.15.1.110

M. Borner, P. Schoffski, R. De-wit, F. Caponigro, G. Comella et al., Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin, European Journal of Cancer, vol.38, issue.3, pp.349-358, 1990.
DOI : 10.1016/S0959-8049(01)00371-9

G. Banna, E. Collovà, V. Gebbia, H. Lipari, P. Giuffrida et al., Anticancer oral therapy: Emerging related issues, Cancer Treatment Reviews, vol.36, issue.8, pp.595-605, 2010.
DOI : 10.1016/j.ctrv.2010.04.005

C. Twelves, S. Gollins, R. Grieve, and L. Samuel, A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer, Annals of Oncology, vol.17, issue.2, pp.239-245, 2006.
DOI : 10.1093/annonc/mdj023

J. Borras, A. Sanchez-hernandez, M. Navarro, M. Martinez, E. Mendez et al., Compliance, satisfaction, and quality of life of patients with colorectal cancer receiving home chemotherapy or outpatient treatment: a randomised controlled trial, BMJ, vol.322, issue.7290, p.826, 2001.
DOI : 10.1136/bmj.322.7290.826

M. Górna? and C. Szczylik, Oral treatment of metastatic breast cancer with capecitabine: what influences the decision-making process?, Eur J Cancer Care (Engl janv, vol.19, issue.11, pp.131-136, 2010.

R. Denois, V. Poirson, J. Nourissat, A. Jacquin, J. Guastalla et al., Adherence with oral chemotherapy: results from a qualitative study of the behaviour and representations of patients and oncologists, European Journal of Cancer Care, vol.366, issue.4, pp.520-527, 2011.
DOI : 10.1111/j.1365-2354.2010.01212.x

C. Frankel and F. Palmieri, Lapatinib Side-Effect Management, Clinical Journal of Oncology Nursing, vol.14, issue.2, pp.223-233, 2010.
DOI : 10.1188/10.CJON.223-233

A. Partridge, J. Avorn, P. Wang, and E. Winer, Adherence to Therapy With Oral Antineoplastic Agents, CancerSpectrum Knowledge Environment, vol.94, issue.9, pp.652-661, 2002.
DOI : 10.1093/jnci/94.9.652

B. Simchowitz, L. Shiman, J. Spencer, D. Brouillard, A. Gross et al., Perceptions and Experiences of Patients Receiving Oral Chemotherapy, Clinical Journal of Oncology Nursing, vol.14, issue.4, pp.447-453, 2010.
DOI : 10.1188/10.CJON.447-453

S. Bordonaro, F. Raiti, D. Mari, A. Lopiano, C. Romano et al., Active homebased cancer treatment, J Multidiscip Healthc, vol.5, pp.137-143, 2012.

C. Catania, F. Didier, M. Leon, A. Sbanotto, L. Mariani et al., Perception that Oral Anticancer Treatments are Less Efficacious: Development of a Questionnaire to Assess the Possible Prejudices of Patients with Cancer, Breast Cancer Research and Treatment, vol.23, issue.4, pp.265-272, 2005.
DOI : 10.1007/s10549-005-3376-y

V. Foulon, P. Schöffski, and P. Wolter, Patient adherence to oral anticancer drugs: an emerging issue in modern oncology, Acta Clin Belg. avr, vol.66, issue.2, pp.85-96, 2011.

P. Pfeiffer, J. Mortensen, B. Bjerregaard, L. Eckhoff, K. Schønnemann et al., Patient preference for oral or intravenous chemotherapy: A randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer, European Journal of Cancer, vol.42, issue.16, pp.2738-2743, 1990.
DOI : 10.1016/j.ejca.2006.06.027

O. Bouché, E. Scaglia, and S. Lagarde, Prerequisites to the administration and prevention of adverse effects of chemotherapy in colorectal cancer]. Bull Cancer (Paris), févr, vol.97, issue.2, pp.265-280, 2010.

R. Halpern, V. Barghout, V. Zarosky, and D. E. Williams, Costs and utilization associated with imatinib adherence in patients with chronic myeloid leukemia or gastrointestinal stromal turmor, JCOM, vol.16, issue.5, p.215, 2009.

H. J. Henk, S. K. Thomas, W. Feng, B. Jean-francois, G. A. Goldberg et al., The impact of non-compliance with imatinib (IM) therapy on health care costs, ASCO Annual Meeting Proceedings (Post-Meeting Edition, pp.2418-6083, 2006.

L. Simon, D. Prebay, A. Beretz, J. Bagot, A. Lobstein et al., Médecines complémentaires et alternatives suivies par les patients cancéreux en France, Bull Cancer, vol.94, issue.5, pp.483-488, 2007.

M. Madame, Vous avez bénéficié d'un suivi collaboratif entre le CHU de Grenoble et la plateforme de santé CPS. Afin d'améliorer l'accompagnement des patients

. Conformément-À-la-loi-informatique and . Liberté, vous disposerez d'un droit d'accès, de rectification et d'opposition aux données vous concernant. Le Dr Dominique Charlety sera la personne

. Nom, Nom : ____________________ Signature : Prénom : __________________ Signature